Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients.
Journal Of Clinical Medicine
M Colombino, C Rozzo, P Paliogiannis, M Casula, A Manca, V Doneddu, MA Fedeli, MC Sini, G Palomba, M Pisano, PA Ascierto, C Caracò, A Lissia, A Cossu, G Palmieri
Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management.
Diagnostics (Basel, Switzerland)
J Wehrle, U Philipp, M Jolic, M Follo, S Hussung, S Waldeck, M Deuter, M Rassner, J Braune, J Rawluk, C Greil, CF Waller, H Becker, J Duque-Afonso, AL Illert, RM Fritsch, F Meiss, J Duyster, N von Bubnoff, F Scherer
Study of Ras Mutations' Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis.
Cancers
A Ottaiano, N Normanno, S Facchini, A Cassata, A Nappi, C Romano, L Silvestro, A De Stefano, AM Rachiglio, C Roma, MR Maiello, S Scala, P Delrio, F Tatangelo, A Di Mauro, G Botti, A Avallone, G Nasti
Clinicopathological Characteristics and Mutation Spectrum of Colorectal Adenocarcinoma With Mucinous Component in a Chinese Cohort: Comparison With Classical Adenocarcinoma.
Frontiers In Oncology
J Chen, L Zhou, J Gao, T Lu, J Wang, H Wu, Z Liang
Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma.
Cancers
M Manzoni, V Marchica, P Storti, B Ziccheddu, G Sammarelli, G Todaro, F Pelizzoni, S Salerio, L Notarfranchi, A Pompa, L Baldini, N Bolli, A Neri, N Giuliani, M Lionetti
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated.
Journal Of Translational Medicine
M Al Hashmi, KS Sastry, L Silcock, L Chouchane, V Mattei, N James, R Mathew, D Bedognetti, V De Giorgi, D Murtas, W Liu, A Chouchane, R Temanni, B Seliger, E Wang, FM Marincola, S Tomei
Ultra-high throughput single-cell analysis of proteins and RNAs by split-pool synthesis.
Communications Biology
M O'Huallachain, FA Bava, M Shen, C Dallett, S Paladugu, N Samusik, S Yu, R Hussein, GR Hillman, S Higgins, M Lou, A Trejo, L Qin, YC Tai, SM Kinoshita, A Jager, D Lashkari, Y Goltsev, S Ozturk, GP Nolan
Impact of the Italian Society of Anatomic Pathology and Diagnostic Cytology Classification of Thyroid Nodules in the Treatment of Indeterminate Follicular Lesions: Five-Year Results at a Single Center.
International Journal Of Endocrinology
M Pastoricchio, A Cubisino, A Lanzaro, M Troian, F Zanconati, S Bernardi, B Fabris, N de Manzini, C Dobrinja
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma.
Nature Communications
A Mitra, MC Andrews, W Roh, MP De Macedo, CW Hudgens, F Carapeto, S Singh, A Reuben, F Wang, X Mao, X Song, K Wani, S Tippen, KS Ng, A Schalck, DA Sakellariou-Thompson, E Chen, SM Reddy, CN Spencer, D Wiesnoski, LD Little, C Gumbs, ZA Cooper, EM Burton, P Hwu, MA Davies, J Zhang, C Bernatchez, N Navin, P Sharma, JP Allison, JA Wargo, C Yee, MT Tetzlaff, WJ Hwu, AJ Lazar, PA Futreal
Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients.
Molecular Oncology
S Schneegans, L Lück, K Besler, L Bluhm, JC Stadler, J Staub, R Greinert, B Volkmer, M Kubista, C Gebhardt, A Sartori, D Irwin, E Serkkola, T Af Hällström, E Lianidou, M Sprenger-Haussels, M Hussong, P Mohr, SW Schneider, J Shaffer, K Pantel, H Wikman
Targeted chemotherapy overcomes drug resistance in melanoma.
Genes & Development
J Yue, R Vendramin, F Liu, O Lopez, MG Valencia, H Gomes Dos Santos, G Gaidosh, F Beckedorff, E Blumenthal, L Speroni, SD Nimer, JC Marine, R Shiekhattar
Comparison of Somatic Mutation Profiles Between Formalin-Fixed Paraffin Embedded Tissues and Plasma Cell-Free DNA from Ovarian Cancer Patients Before and After Surgery.
Bioresearch Open Access
M Jagelkova, K Zelinova, Z Laucekova, M Bobrovska, Z Dankova, M Grendar, K Dokus
RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML.
Blood Advances
AL Brown, P Arts, CL Carmichael, M Babic, J Dobbins, CE Chong, AW Schreiber, J Feng, K Phillips, PPS Wang, T Ha, CC Homan, SL King-Smith, L Rawlings, C Vakulin, A Dubowsky, J Burdett, S Moore, G McKavanagh, D Henry, A Wells, B Mercorella, M Nicola, J Suttle, E Wilkins, XC Li, J Michaud, P Brautigan, P Cannon, M Altree, L Jaensch, M Fine, C Butcher, RJ D'Andrea, ID Lewis, DK Hiwase, E Papaemmanuil, MS Horwitz, G Natsoulis, HY Rienhoff, N Patton, S Mapp, R Susman, S Morgan, J Cooney, M Currie, U Popat, T Bochtler, S Izraeli, K Bradstock, LA Godley, A Krämer, S Fröhling, AH Wei, C Forsyth, H Mar Fan, NK Poplawski, CN Hahn, HS Scott
Prognostic implications of EGFR protein expression in sporadic colorectal tumors: Correlation with copy number status, mRNA levels and miRNA regulation.
Scientific Reports
S Del Carmen, LA Corchete, R Gervas, A Rodriguez, M Garcia, JA Álcazar, J García, O Bengoechea, L Muñoz-Bellvis, JM Sayagués, M Abad
Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy.
Nature Cancer
S Valpione, E Galvani, J Tweedy, PA Mundra, A Banyard, P Middlehurst, J Barry, S Mills, Z Salih, J Weightman, A Gupta, G Gremel, F Baenke, N Dhomen, PC Lorigan, R Marais
Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design.
Plos One
A Aguilera-Diaz, I Vazquez, B Ariceta, A Mañú, Z Blasco-Iturri, S Palomino-Echeverría, MJ Larrayoz, R García-Sanz, MI Prieto-Conde, M Del Carmen Chillón, A Alfonso-Pierola, F Prosper, M Fernandez-Mercado, MJ Calasanz
Publication Date: 2020
Variant appearance in text: NRAS: 182A>G; Gln61Arg
Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer.
Plos One
C Franczak, A Witz, K Geoffroy, J Demange, M Rouyer, M Husson, V Massard, C Gavoille, A Lambert, P Gilson, N Gambier, J Scala-Bertola, JL Merlin, A Harlé
Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic features.
Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy.
Cancer Science
M Sugimori, K Sugimori, H Tsuchiya, Y Suzuki, S Tsuyuki, Y Kaneta, A Hirotani, K Sanga, Y Tozuka, S Komiyama, T Sato, S Tezuka, Y Goda, K Irie, H Miwa, Y Miura, T Ishii, T Kaneko, M Nagahama, W Shibata, A Nozaki, S Maeda
A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants.
Scientific Reports
I Ticha, J Hojny, R Michalkova, O Kodet, E Krkavcova, N Hajkova, K Nemejcova, M Bartu, R Jaksa, M Dura, M Kanwal, AS Martinikova, L Macurek, P Zemankova, Z Kleibl, P Dundr
Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors.
Nature Communications
MJ Sale, E Minihane, NR Monks, R Gilley, FM Richards, KP Schifferli, CL Andersen, EJ Davies, MA Vicente, E Ozono, A Markovets, JR Dry, L Drew, V Flemington, T Proia, DI Jodrell, PD Smith, SJ Cook
Limited Utility of Circulating Cell-Free DNA Integrity as a Diagnostic Tool for Differentiating Between Malignant and Benign Thyroid Nodules With Indeterminate Cytology (Bethesda Category III).
Frontiers In Oncology
S Thakur, A Tobey, B Daley, S Auh, M Walter, D Patel, N Nilubol, E Kebebew, A Patel, K Jensen, V Vasko, J Klubo-Gwiezdzinska
In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site.
Leukemia
A Chaturvedi, R Goparaju, C Gupta, J Weder, T Klünemann, MM Araujo Cruz, A Kloos, K Goerlich, R Schottmann, B Othman, EA Struys, H Bähre, D Grote-Koska, K Brand, A Ganser, M Preller, M Heuser
Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
Cell Death & Disease
I Das, M Wilhelm, V Höiom, R Franco Marquez, F Costa Svedman, J Hansson, R Tuominen, S Egyhàzi Brage
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers.
Nature Medicine
AR Parikh, I Leshchiner, L Elagina, L Goyal, C Levovitz, G Siravegna, D Livitz, K Rhrissorrakrai, EE Martin, EE Van Seventer, M Hanna, K Slowik, F Utro, CJ Pinto, A Wong, BP Danysh, FF de la Cruz, IJ Fetter, B Nadres, HA Shahzade, JN Allen, LS Blaszkowsky, JW Clark, B Giantonio, JE Murphy, RD Nipp, E Roeland, DP Ryan, CD Weekes, EL Kwak, JE Faris, JY Wo, F Aguet, I Dey-Guha, M Hazar-Rethinam, D Dias-Santagata, DT Ting, AX Zhu, TS Hong, TR Golub, AJ Iafrate, VA Adalsteinsson, A Bardelli, L Parida, D Juric, G Getz, RB Corcoran
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.
Journal Of Translational Medicine
T Seremet, Y Jansen, S Planken, H Njimi, M Delaunoy, H El Housni, G Awada, JK Schwarze, M Keyaerts, H Everaert, D Lienard, V Del Marmol, P Heimann, B Neyns
Differentiated Thyroid Carcinoma in Pediatric Age: Genetic and Clinical Scenario.
Frontiers In Endocrinology
F Galuppini, F Vianello, S Censi, S Barollo, L Bertazza, S Carducci, C Colato, J Manso, M Rugge, M Iacobone, S Watutantrige Fernando, G Pennelli, C Mian
Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital.
Cancers
J Simarro, R Murria, G Pérez-Simó, M Llop, N Mancheño, D Ramos, I Juan, E Barragán, B Laiz, E Cases, E Ansótegui, J Gómez-Codina, J Aparicio, C Salvador, Ó Juan, S Palanca